Skip to main content
Premium Trial:

Request an Annual Quote

GE Launches $250M Life Sciences, Diagnostics Investment Fund

NEW YORK (GenomeWeb News) – GE has launched a new $250 million equity fund to invest in "highly promising" young companies developing or offering life sciences tools, diagnostics, and health care information technologies, GE Healthcare said today.

The GE Healthymagination Fund, part of the company's $6 billion Healthymagination Initiative, will be global in reach and it will harness the capabilities of GE Healthcare, GE Capital, and GE Global Research.

In the area of broad-based diagnostics, the fund will support companies developing or offering molecular diagnostics, novel imaging agents, patient monitoring, and other diagnostic tools.

In the life sciences, the GE fund will invest in tools for biopharmaceutical research and development, tools used for making vaccines, and stem cell R&D.

On the health care IT front, the fund will support electronic medical records, value-added data services, clinical information systems, and health care information exchanges.

"[T]he new fund "gives us an opportunity to work with emerging companies to support their development, as well as provide them access to our technology base and our global presence," GE Chairman and CEO Jeffrey Immelt said in a statement. "As GE works on solutions to healthcare's biggest challenges, it is vitally important that we support the development of companies with promising technologies or business models that are aligned with our strategy and have the potential to shape the future of healthcare."

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.